Bastide Le Confort Medical


De facto maintained guidance; more disposals to propel debt reduction

15/05/24 -"Bastide reported stronger organic growth in Q3 than in the previous two quarters. The group is currently spinning off two Swiss subsidiaries, which has led to a downward revision of the FY sales ..."

Pages
52
Language
English
Published on
15/05/24
You may also be interested by these reports :
17/05/24
Clariane communicated more details regarding its projected capital increases and the entry of a new anchor shareholder in its capital. We take this ...

17/05/24
We have incorporated the detailed information provided by Clariane regarding its projected capital increases. This has resulted in only minor changes ...

16/05/24
On the back of the promising beginning to 2024, which was a combination of 1/ normalising market demand in Europe (the lynchpin geography); 2/ the ...

16/05/24
As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO